Abeona Therapeutics (ABEO)
(Delayed Data from NSDQ)
$6.67 USD
-0.07 (-1.04%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $6.66 -0.01 (-0.15%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$6.67 USD
-0.07 (-1.04%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $6.66 -0.01 (-0.15%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Philips (PHG) Showcases New AI-Based Solutions at the RSNA
by Zacks Equity Research
Koninklijke Philips (PHG) banks on its new AI solutions to address issues faced by Radiology experts in the healthcare industry and drive prospects.
Philips (PHG) to Showcase New Innovations & Cardiac Solutions
by Zacks Equity Research
Philips (PHG) is launching cardiac solutions to further benefit from its tried-and-tested strategic operational decision to build new products to attract more customers.
Philips (PHG) Expands Partnership to Build Angio CT Solution
by Zacks Equity Research
Philips (PHG) is building the world's first spectral detector angio CT solution by forging an alliance with the Leiden University Medical Center.
Philips (PHG) Alerts Users of Health Hazards of Therapy Masks
by Zacks Equity Research
Philips (PHG) cautions customers against health hazards faced by the users of CPAP or Bi-Level PAP therapy masks with magnetic headgear.
Ultragenyx's (RARE) Q2 Earnings Miss Estimates, Revenues Up
by Zacks Equity Research
Ultragenyx (RARE) reports a wider-than-expected loss in the second quarter. Nevertheless, revenues marginally beat estimates.
Philips (PHG) Expands AI Portfolio With SmartSpeed Solution
by Zacks Equity Research
Koninklijke Philips (PHG) announces that its latest AI-powered MR acceleration software SmartSpeed will be showcased as part of the AI-powered precision diagnosis portfolio at ECR.
Pfizer (PFE) Discloses Autoimmune Drug Deal With Priovant
by Zacks Equity Research
Pfizer (PFE) announces the name of the new company that it formed with its partner, Roivant Sciences (ROIV), to develop and market its dual TYK2/JAK1 inhibitor.
F-star (FSTX) Stock Rises on Buyout Offer From Sino Biopharm
by Zacks Equity Research
Sino Biopharmaceutical, through its wholly-owned subsidiary, is set to acquire F-star (FSTX) for $7.12 per share in cash. The transaction is likely to close by second-half 2022.
Acer Therapeutics (ACER) Gets CRL for Urea Cycle Disorders Drug
by Zacks Equity Research
Acer Therapeutics' (ACER) new drug application for ACER-001 to treat urea cycle disorders faces rejection from the FDA. Share price falls 21% following the announcement.
ObsEva's (OBSV) Yselty Gets EU Nod to Treat Uterine Fibroids
by Zacks Equity Research
ObsEva's (OBSV) Yselty receives its first marketing approval in the European Union for the treatment of uterine fibroids in adult women. Shares were up 11% in pre-market trading following the news.
Clovis (CLVS) Up 19.4% on Upbeat Data From Solid Tumor Study
by Zacks Equity Research
Clovis Oncology (CLVS) reports favorable data from a study, which supports the potential clinical utility of FAP-2286, its targeted radiotherapy candidate, as a treatment for advanced solid tumors.
FDA Committee Endorses bluebird's (BLUE) Thalassemia Therapy
by Zacks Equity Research
An FDA advisory committee favors approval for bluebird bio's (BLUE) beti-cel to treat transfusion-dependent thalassemia. A final decision by the regulatory body is expected on Aug 19, 2022.
FDA Committee Recommends bluebird's (BLUE) CALD Therapy
by Zacks Equity Research
An FDA advisory committee supports approving bluebird bio's (BLUE) eli-cel for treating cerebral adrenoleukodystrophy. NASDAQ halts trading BLUE's common stock on Jun 9 and 10.
bluebird (BLUE) Up as FDA Nod Likely for Thalassemia Therapy
by Zacks Equity Research
Based on briefing documents issued by the FDA, a positive regulatory approval is expected on bluebird bio's (BLUE) gene-therapy for treating thalassemia.
AstraZeneca (AZN) Breast Cancer Drug Cuts Risk of Death to Half
by Zacks Equity Research
Data from a late-stage study shows that AstraZeneca's (AZN) Enhertu meets superior and clinically meaningful progression-free survival and overall survival in HER2-low metastatic breast cancer patients.
BioMarin (BMRN) Delays FDA Re-Submission for Hemophilia Drug
by Zacks Equity Research
BioMarin (BMRN) posts follow-up data from a phase I/II study on its gene-therapy candidate for hemophilia A. However, the stock falls 7% as management plans to defer the candidate's BLA filing.
Amicus' (FOLD) Galafold Aids Growth, Overdependence a Woe
by Zacks Equity Research
Currently, Amicus Therapeutics (FOLD) has only one marketed product in its portfolio, the Fabry disease drug Galafold. The FDA is reviewing FOLD's filings that seek approval for Pompe disease.
Verrica (VRCA) Down 64% as Molluscum Drug Gets CRL From FDA
by Zacks Equity Research
Verrica Pharmaceuticals' (VRCA) new drug application for VP-102 to treat molluscum contagiosum faces rejection from the FDA for a second time.
Aerie (AERI) Starts Late-Stage Study to Treat Dry Eye Disease
by Zacks Equity Research
Aerie Pharmaceutials (AERI) doses the first patient in a phase III study on its investigational TRMP8 agonist drug for the treatment of dry eye disease.
Athersys (ATHX) Down as Ischemic Stroke Study Fails to Meet Goal
by Zacks Equity Research
While a mid-stage/late-stage study evaluating Athersys' (ATHX) stem cell treatment for ischemic stroke misses out on its primary endpoint, top-line data shows evidence of therapeutic impact.
Enanta's (ENTA) RSV Drug Fails to Meet Study Goal, Stock Drops
by Zacks Equity Research
While a mid-stage study evaluating Enanta's (ENTA) RSV candidate misses out on its primary endpoint, a statistically huge number of subjects achieved undetectable RSV RNA at the end of treatment.
AVROBIO (AVRO) Stock Up on Upbeat Data From Cystinosis Study
by Zacks Equity Research
Results from AVROBIO's (AVRO) phase I/II study, which is evaluating its gene-therapy candidate for cystinosis, show the latter's potential to stabilize or reduce the impact of cystinosis on different tissues.
Ultragenyx (RARE) Acquires Rights of AAV Gene Therapy Candidate
by Zacks Equity Research
Ultragenyx (RARE) signs an exclusive license agreement with Abeona Therapeutics to acquire the latter's gene therapy candidate, ABO-102 (now UX111), for treating Sanfilippo syndrome type A.
Philips' (PHG) Launches a Range of New Products at EuroPCR 2022
by Zacks Equity Research
Philips' (PHG) launches innovative new solutions to attract customers amid a global supply crunch and drive top-line growth.
AbbVie (ABBV) Buys Option Rights to NextGen Inflammation Drug
by Zacks Equity Research
AbbVie (ABBV) receives the option to license worldwide rights for certain IL-2 muteins, including the next-generation inflammatory candidate, CUG252 from Cugene